
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics Inc has a strong positive outlook due to the advanced clinical data showing that its candidate RLY-2608 demonstrates superior efficacy and tolerability compared to capivasertib, which may lead to swift market acceptance. Additionally, RLY-2608 is anticipated to increase the overall penetration of PI3Ka inhibitors and potentially expand the market opportunity, which is currently valued at approximately $700 million with ongoing growth. The company's innovative Dynamo platform, focusing on precision medicine for oncology and genetic diseases, underlines its commitment to addressing previously challenging drug targets, further enhancing its growth prospects.
Bears say
The negative outlook on Relay Therapeutics Inc. stems from significant concerns regarding the projected median progression-free survival (mPFS) for its drug candidates, which is expected to decline by approximately 80%, from 24 months to just 5 months, raising alarm regarding the efficacy of these therapies. Additionally, the commercial launch of its product inavolisib has been disappointing due to safety liabilities linked to the drug’s inhibition mechanism, particularly affecting metabolically unfit patients, further undermining market expectations for a first-line product. Furthermore, declining sales in related therapeutics, such as Piqray, due to heightened competition in the market, illustrate further pressures on the company's financial prospects and overall market position.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares